EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Distinct Roles of IL ‐4, IL ‐13, and IL ‐22 in Human Skin Barrier Dysfunction and Atopic Dermatitis

Paolo D'Avino, Juno Kim, Manru Li, Philipp Gessner, Patrick Westermann, Yagız Pat, Carina Beha iD, Claudia Traidl-Hoffmann iD, Jeremy Bost, Nicolas Gaudenzio iD, Christoph B Messner, Cezmi A Akdis iD and 1 more

Allergy · 2026-02 · 81 (2) · 480-497

DOI: 10.1111/all.70060 ↗

At a glance

Journal article in Allergy, published online on 2025-09-23. Written by Paolo D'Avino and 12 co-authors. Institution: Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland. Major MEDLINE topics: Dermatitis, Atopic, Interleukins, Interleukin-4, Interleukin-13. Cited 44 times so far (Crossref); 54 references. The full text is freely available (open access, CC BY 4.0). Funded by: This work was funded by SciBase AB, GenoSkin SAS, and the Swiss National Foundation. SciBase AB contributed EIS instruments and electrodes for the study and co….

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Atopic dermatitis (AD) is a chronic type‐2 inflammatory skin disease characterized by eczema and epithelial barrier dysfunction. Along with the type‐2 cytokines IL‐4 and IL‐13, IL‐22 contributes to AD pathogenesis. To date, most skin studies rely on reconstructed keratinocytes, which do not represent the real skin response.

Objective

Here, we report the distinct effects of IL‐4, IL‐13, and IL‐22 on bio‐stabilized human skin with intact barriers and immune cells.

Methods

Spatial transcriptomics on AD ‐lesions and non‐lesional skin was performed. Ex vivo skin barrier integrity was evaluated using electrical impedance spectroscopy ( EIS ), RNA ‐sequencing, and untargeted proteomics, complemented by analyses of skin biopsies from dupilumab‐treated AD patients.

Results

Spatial transcriptomics demonstrated that AD lesions showed reduced expression of key barrier genes, including CLDN1, FLG, and FLG2. IL‐4, IL‐13, and IL‐22 disrupted the skin barrier in the ex vivo human skin. Combining type‐2 cytokines and IL‐22 alone downregulated genes critical for barrier function and keratinization. In addition, IL‐4 and IL‐13 downregulated antimicrobial peptides, while IL‐22 upregulated them. Interestingly, IL‐4 and IL‐13 reduced IL‐22Rα1, and IL‐22 upregulated IL‐4Rα, suggesting immune cross‐regulation. Proteomic analysis confirmed that all three cytokines (IL‐4, IL‐13, and IL‐22) reduced the expression of key skin barrier proteins, particularly filaggrin and claudin‐1. Dupilumab treatment of AD patients for 3 months restored IL‐4/IL‐13‐dysregulated genes, whereas it had limited effect on IL22‐associated pathways.

Conclusion

This comprehensive study provides insights into the distinct immune profiles following IL‐4, IL‐13, and IL‐22 stimulation on human skin, highlighting their complex interplay in disrupting skin barrier function and modulating innate immune responses.

Subjects

MeSH terms (MEDLINE)

Dermatitis, AtopicInterleukinsInterleukin-4Interleukin-13SkinHumansInterleukin-22Filaggrin ProteinsProteomicsAdultKeratinocytesFemale

Author keywords

atopic dermatitisdupilumab (anti‐IL4Rα antibody)electrical impedance spectroscopyex vivo human skininflammationinterleukin‐13interleukin‐22interleukin‐4skin barrier

Substances

Interleukin-22InterleukinsInterleukin-4Interleukin-13Filaggrin ProteinsFLG protein, humanIL13 protein, humanIL4 protein, human

Authors and institutions

  • Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
  • CK CARE - Christine Kühne Center for Allergy Research and Education, Davos, Switzerland.
  • Department of Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
  • Institute of Environmental Medicine, Helmholtz Zentrum München, Augsburg, Germany.
  • SciBase AB, Sundbyberg, Sweden.
  • Toulouse Institute for Infectious and Inflammatory Disease (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France.

ORCID profiles: Carina Beha, Claudia Traidl-Hoffmann, Nicolas Gaudenzio, Cezmi A Akdis, Yasutaka Mitamura

Funding

  • This work was funded by SciBase AB, GenoSkin SAS, and the Swiss National Foundation. SciBase AB contributed EIS instruments and electrodes for the study and co…

Cite

APA

D'Avino, P., Kim, J., Li, M., Gessner, P., Westermann, P., Pat, Y., Beha, C., Traidl-Hoffmann, C., Bost, J., Gaudenzio, N., Messner, C. B., Akdis, C. A., & Mitamura, Y. (2026). Distinct Roles of IL ‐4, IL ‐13, and IL ‐22 in Human Skin Barrier Dysfunction and Atopic Dermatitis. Allergy, 81(2), 480-497. https://doi.org/10.1111/all.70060

Vancouver

D'Avino P, Kim J, Li M, Gessner P, Westermann P, Pat Y, et al. Distinct Roles of IL ‐4, IL ‐13, and IL ‐22 in Human Skin Barrier Dysfunction and Atopic Dermatitis. Allergy. 2026;81(2):480-497. doi:10.1111/all.70060

BibTeX
@article{DAvino2026,
  author = {D'Avino, Paolo and Kim, Juno and Li, Manru and Gessner, Philipp and Westermann, Patrick and Pat, Yagız and Beha, Carina and Traidl-Hoffmann, Claudia and Bost, Jeremy and Gaudenzio, Nicolas and Messner, Christoph B and Akdis, Cezmi A and Mitamura, Yasutaka},
  title = {Distinct Roles of IL ‐4, IL ‐13, and IL ‐22 in Human Skin Barrier Dysfunction and Atopic Dermatitis},
  journal = {Allergy},
  year = {2026},
  volume = {81},
  number = {2},
  pages = {480--497},
  doi = {10.1111/all.70060}
}
Start for free →